Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib

K.J. Gotink, M.N. Rovithi, R.R. de Haas, R.J. Honeywell, H. Dekker, D. Poel, K. Azijli, G.J. Peters, H.J. Broxterman, H.M.W. Verheul

Research output: Contribution to journalArticleAcademicpeer-review

43 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)119-129
JournalCellular oncology
Issue number2
Publication statusPublished - 2015

Cite this